RxDoctor Payments Data

Paul Garrett, MD

Cardiovascular Disease · Baton Rouge, LANPI 1639160823

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Astellas Pharma US Inc at 59.2% of the total. Reporting peaked in 2019 at $10,948 and has fallen 87.3% since, to $1,393 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,290in general payments, 2019–2025

Across 546 payments — averaging $44.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$14K
  • Johnson & Johnson$2K
  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Amgen$682
  • Pfizer$598
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$13,59056%
  • Travel & lodging$1341%
  • Food & beverage$10,54943%
  • Other$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,290 in reported general payments places this provider in the 90th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$263,470
Medicare patients
1,008
Services billed
7,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban397$376,268
EntrestoSacubitril/Valsartan191$201,371
XareltoRivaroxaban195$179,652
JardianceEmpagliflozin38$53,001
Repatha SureclickEvolocumab47$40,262
NexlizetBempedoic Acid/Ezetimibe29$22,248
Metoprolol Succinate631$8,430
Atorvastatin Calcium623$7,331
VascepaIcosapent Ethyl13$5,242
Rosuvastatin Calcium269$4,043
Flecainide Acetate82$3,964
Ezetimibe141$2,984
Ranolazine ErRanolazine13$2,698
Losartan Potassium184$2,232
Diltiazem 24hr Er (La)Diltiazem Hcl15$2,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$598$376,268397 claims
NovartisEntresto$1,319$201,371191 claims
Johnson & JohnsonXarelto$1,740$179,652195 claims
Boehringer IngelheimJardiance$203$53,00138 claims
Esperion Therapeutics, Inc.Nexlizet$546$22,24829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →